Health Care & Life Sciences » Pharmaceuticals | Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
130,880.00
129,822.00
143,180.00
141,340.00
143,413.00
257,460
Total Accounts Receivable
2,159.00
3,654.00
16,331.00
20,268.00
17,601.00
28,780
Inventories
-
5,170.00
1,294.00
779.00
840.00
994
Other Current Assets
2,575.00
3,084.00
5,742.00
11,788.00
8,003.00
11,898
Total Current Assets
135,614.00
141,730.00
166,547.00
174,175.00
169,857.00
299,132
Net Property, Plant & Equipment
2,198.00
2,437.00
4,570.00
5,015.00
5,306.00
4,417
Total Investments and Advances
500.00
785.00
-
800.00
-
600
Intangible Assets
5,037.00
26,724.00
38,752.00
27,819.00
26,069.00
24,542
Other Assets
-
28.00
3,181.00
2,465.00
4,193.00
3,439
Total Assets
143,349.00
171,704.00
213,050.00
210,374.00
205,425.00
332,130
Accounts Payable
661.00
835.00
5,328.00
4,555.00
4,394.00
Other Current Liabilities
32,190.00
6,951.00
45,989.00
45,765.00
65,969.00
Total Current Liabilities
32,851.00
7,786.00
51,317.00
50,320.00
70,363.00
Provision for Risks & Charges
-
-
25,000.00
25,000.00
-
Deferred Taxes
-
-
-
100.00
100.00
Other Liabilities
66,374.00
3,101.00
3,706.00
3,724.00
3,575.00
Total Liabilities
99,225.00
10,887.00
80,023.00
79,044.00
74,038.00
Common Equity (Total)
44,124.00
160,817.00
133,027.00
131,330.00
131,387.00
Total Shareholders' Equity
44,124.00
160,817.00
133,027.00
131,330.00
131,387.00
Total Equity
44,124.00
160,817.00
133,027.00
131,330.00
131,387.00
Liabilities & Shareholders' Equity
143,349.00
171,704.00
213,050.00
210,374.00
205,425.00

About Vanda Pharmaceuticals

View Profile
Address
2200 Pennsylvania Avenue NW
Washington District of Columbia 20037
United States
Employees -
Website http://www.vandapharma.com
Updated 07/08/2019
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.